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ABSTRACT
Objective To assess the impact of describing an antibody- 
positive test result using the terms Immunity and Passport 
or Certificate, alone or in combination, on perceived risk of 
becoming infected with severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) and protective behaviours.
Design 2×3 experimental design.
Setting Online.
Participants 1204 adults from a UK research panel.
Intervention Participants were randomised to receive one 
of six descriptions of an antibody test and results showing 
SARS- CoV-2 antibodies, differing in the terms describing 
the type of test (Immunity vs Antibody) and the test result 
(Passport vs Certificate vs Test).
Main outcome measures Primary outcome: proportion 
of participants perceiving no risk of infection with SARS- 
CoV-2 given an antibody- positive test result. Other 
outcomes include: intended changes to frequency of hand 
washing and physical distancing.
Results When using the term Immunity (vs Antibody), 
19.1% of participants (95% CI 16.1% to 22.5%) (vs 9.8% 
(95% CI 7.5% to 12.4%)) perceived no risk of catching 
coronavirus given an antibody- positive test result (adjusted 
OR (AOR): 2.91 (95% CI 1.52 to 5.55)). Using the terms 
Passport or Certificate—as opposed to Test—had no 
significant effect (AOR: 1.24 (95% CI 0.62 to 2.48) and 
AOR: 0.96 (95% CI 0.47 to 1.99) respectively). There was 
no significant interaction between the effects of the test 
and result terminology. Across groups, perceiving no risk of 
infection was associated with an intention to wash hands 
less frequently (AOR: 2.32 (95% CI 1.25 to 4.28)); there 
was no significant association with intended avoidance of 
physical contact (AOR: 1.37 (95% CI 0.93 to 2.03)).
Conclusions Using the term Immunity (vs Antibody) to 
describe antibody tests for SARS- CoV-2 increases the 
proportion of people believing that an antibody- positive 
result means they have no risk of catching coronavirus in 
the future, a perception that may be associated with less 
frequent hand washing.
Trial registration number Open Science Framework: 
https:// osf. io/ tjwz8/ files/
INTRODUCTION
At the height of the first wave of the 
COVID-19 pandemic, about a third of the 
world’s population is estimated to have been 
in lockdown, with all but essential workers 
largely confined to home.1
Without an effective treatment or vaccine, 
testing for infection combined with contact 
tracing and isolation will be central to effec-
tive strategies to ease populations out of lock-
down while keeping the basic reproduction 
number (R0) below 1.
2
Testing for antibodies to severe acute respi-
ratory syndrome coronavirus 2 (SARS- CoV-2) 
is a possible complement to testing for active 
infection to identify those who have developed 
antibodies to the virus and so may be able to 
return to work and other activities without 
significantly increasing transmission rates.3 
These tests have been variously described in 
the media as Immunity Passports,4 5 Immu-
nity Certificates,6 7 Immunity Cards8 and 
Release Certificates.9 Unfortunately, the use 
of these terms implies a certainty unmatched 
by current evidence about antibody tests.10 
But whether these terms actually encourage 
a misplaced sense of certainty even before 
Strengths and limitations of this study
 ► This study provides the first experimental evidence 
for the potentially adverse impact on risk percep-
tions and protective behaviours of using the term 
Immunity—as opposed to Antibody—to describe 
severe acute respiratory syndrome coronavirus 2 
antibody tests and their results.
 ► It provides timely evidence to inform policy and re-
search to mitigate these effects to realise the poten-
tial benefits of such tests.
 ► Participants were responding to a hypothetical test 
and asked to imagine that they had received a test 
result that had detected antibodies.
 ► Protective behaviours of hand washing and physical 
distancing were measured using single items as-
sessing behavioural intentions.
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testing is widely available is unknown and the focus of the 
current study.
Uncertainties inherent in tests for antibodies to 
SARS- CoV-2 include the extent and duration of immunity 
conferred.11 They also include the uncertainties inherent 
in any test regarding the proportion of those who would 
be correctly identified. This depends on the test perfor-
mance—its sensitivity and specificity—as well as the popu-
lation prevalence of the tested condition.12 Given these 
uncertainties, those who receive a test result indicating 
the presence of antibodies will have a residual risk of 
becoming infected by SARS- CoV-2 in the future.
Understanding that there is this residual risk—
although one that is difficult to quantify at present—will 
be important to minimise transmission that could arise 
from those receiving ‘antibody positive’ test results. If 
people testing positive perceive that they have no risk 
of becoming infected by the virus, they may ignore any 
future symptoms of infection and facilitate transmission 
if they fail to self- isolate appropriately. Such a perception 
may also overgeneralise to a belief that they are unable 
to transmit infection through contact with contaminated 
surfaces. Regardless of antibody status, all individuals can 
indirectly transmit the virus between surfaces by touch. 
Hand washing or sanitising therefore needs to remain 
frequent.
Evidence from other testing programmes suggests 
that interpreting a low- risk result to mean no risk can be 
reduced by verbal and numerical expressions of residual 
risk when presenting test results.13 14 But even before 
testing programmes are in place, the terms commonly 
used to describe these tests—Immunity Passport or Certif-
icates—may inadvertently be fuelling a misplaced sense 
of certainty about their results. It is unknown whether 
describing these tests as being for immunity—as opposed 
to antibodies—or their results as passports or certificates 
increases misunderstanding of the residual risk inherent 
in an antibody- positive test result and thereby reducing 
adherence to protective behaviours and increasing risk of 
transmission.15
This study was designed to test two hypotheses: 
describing a test indicating the presence of antibodies 
using the term Immunity (vs Antibody), and describing 
test results as Passports or Certificates (vs Test), increases 
the likelihood that those with this test result erroneously 
perceive they have no risk of becoming infected in the 
future with coronavirus.
METHODS
The protocol was preregistered on the Open Science 
Framework https:// osf. io/ tjwz8/ Study 2.
The statistical analysis plan was prespecified and 
uploaded to the Open Science Framework prior to 
receipt of the data https:// osf. io/ tjwz8/ Study 2.
An initial study with similar methods was conducted 
https:// osf. io/ tjwz8/ Study 1 but, due to an error, the 
intervention was not correctly programmed. This study is 
therefore not reported.
Design
The study was an online experiment using a 2×3 factorial 
design, with participants randomised, with an equal allo-
cation ratio, to one of six groups varying in the descrip-
tion of an antibody test and a result showing the presence 
of antibodies. These descriptions differed only in the 
term used for what was being tested (Immunity vs Anti-
body) and the term used for the test result (Passport vs 
Certificate vs Test).
Participants
A quota sample of 1204 adults was recruited via Predictiv, 
the Behavioural Insights Team’s online experimentation 
platform (https://www. bi. team/ bi- ventures/ predictiv/) 
comprising 500 000 adults in the UK. Quotas were based 
on age, gender and UK region to achieve a sample 
broadly representative of the UK population. Up to 1373 
clicked on the link to enter the study of whom 1214 
subsequently completed the study. Ten were excluded for 
failing to meet quality checks (eg, the unique participant 
identifier was missing, or the participant had entered the 
survey more than once). Participants were reimbursed 
in points (equivalent to £1) which could be redeemed in 
cash, gift vouchers or charitable donations. Participants 
did not know the topic of the study prior to participation. 
All participants had provided opt- in consent to take part 
in surveys when they signed up to the online panel. No 
identifiable data were collected as part of the survey. All 
data collected by Predictiv are processed in line with their 
published privacy policy (http://www. predictiv. co. uk/ 
privacy- policy. html).
Patient and public involvement
Due to the rapid nature of this research, the public was 
not involved in the development of the study.
Power
The sample size was chosen pragmatically without refer-
ence to a specific power calculation. We fitted a full linear 
model with two levels for test type (immunity/antibody), 
three levels for result type (passport/certificate/test) 
and an interaction term. Conservatively, we then had an 
80% chance of detecting, at a 5% significance level, an 
increase in the primary outcome measure from 50% in 
a baseline group to 64% in another group. The power 
calculation was done using http:// powerandsamplesize. 
com/, taking 50% as the baseline to provide a conserva-
tive estimate of power.
Randomisation
Participants were randomised to groups by random 
number generation. A random number between 1 and 6 
was generated for every participant on entry to the study 
to determine which description they saw, with each of 
the six numbers corresponding to one of the six descrip-
tions. As this is based on true randomness, the number 
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of participants within each group can vary due to chance 
(see table 1 for numbers in each group).
Intervention
The intervention comprised a description of antibody 
testing and test results indicating the presence of anti-
bodies (see box 1 for one example and (online supple-
mentary material S1) for wording of all six descriptions). 
These differed across six groups in test name of results 
indicating the presence of antibodies. All descriptions 
included the information that the result would mean a 
lower risk of future infection and transmission, and that 
people with this result could return to work earlier.
Outcome measures
Wording of the items used for each measure is shown in 
online supplementary material S2. Response options to 
all outcome measures are shown in table 2.
Primary outcome
Proportion of participants perceiving an antibody- positive 
test result to mean no risk of catching coronavirus in 
the future: assessed in response to a question with four 
response options.
Secondary outcomes
Perceived likelihood of catching coronavirus in the 
future, assessed on a visual analogue scale from 0% to 
100%.
Intention to engage in hand washing less or more 
frequently than now, given an antibody- positive test result: 
assessed in response to a question with five response 
options.
Intention to avoid physical contact with others outside 
the home more or less frequently than now, given an 
antibody- positive test result: assessed in response to a 
question with five response options.
Interest in undergoing the test if offered today: assessed 
in response to a question with four response options.
Other measures
Demographic characteristics: age, gender, level of educa-
tion and geographical region of residence. Employment 
status, planned to be included, was omitted due to a tech-
nical error.
Statistical analyses
A detailed statistical analysis plan is available on the Open 
Science Framework, specified prior to receipt of the data 
https:// osf. io/ tjwz8/ Study 2. Binary logistic regression 
was used to assess the impact of test type (immunity/
antibody) and result type (passport/certificate/test) 
on the odds of believing the antibody test result means 
there is no risk of future infection. An interaction term 
was included in the model.16 The analysis was repeated 
adjusting for age (including a quadratic function to 
model a non- linear relationship), gender, education and 
Table 1 Demographic characteristics of participants by experimental group (n=1204)
Characteristics
Immunity Antibody
All Passport Certificate Test Passport Certificate Test
(n=1204) (n=187) (n=235) (n=179) (n=219) (n=209) (n=175)
Gender, n (%)
  Female 606 (50.3) 86 (46.0) 126 (53.6) 94 (52.5) 112 (51.1) 98 (46.9) 90 (51.4)
  Male 598 (49.7) 101 (54.0) 109 (46.4) 85 (47.5) 107 (48.9) 111 (53.1) 85 (48.6)
Age, median (IQR) 36 (32) 35 (34) 36 (34) 36 (31) 38 (32) 34 (27) 36 (31)
Education, n (%)
  Below degree 888 (73.8) 139 (74.3) 177 (75.3) 126 (70.4) 165 (75.3) 150 (71.8) 131 (74.9)
  Degree or above 291 (24.2) 45 (24.1) 52 (22.1) 49 (27.4) 49 (22.4) 55 (26.3) 41 (23.4)
  Missing 25 (2.1) 3 (1.6) 6 (2.6) 4 (2.2) 5 (2.3) 4 (1.9) 3 (1.7)
UK region, n (%)
  England—London 160 (13.3) 24 (12.8) 33 (14.0) 27 (15.1) 25 (11.4) 27 (12.9) 24 (13.7)
  England—Midlands 189 (15.7) 38 (20.3) 34 (14.5) 24 (13.4) 30 (13.7) 32 (15.3) 31 (17.7)
  England—South and East 373 (31.0) 48 (25.7) 74 (31.5) 51 (28.5) 75 (34.2) 74 (35.4) 51 (29.1)
  England—North 308 (25.6) 46 (24.6) 65 (27.7) 50 (27.9) 59 (26.9) 43 (20.6) 45 (25.7)
  Scotland/Wales/NI 174 (14.5) 31 (16.6) 29 (12.3) 27 (15.1) 30 (13.7) 33 (15.8) 24 (13.7)
Box 1 Immunity Passport: one of the six descriptions of 
an antibody- positive test result
Immunity Passport
Scientists are developing tests to see who has already had coronavirus.
No test is 100% effective.
This means that those who test ‘positive’ would have:
 ► Lower risk of catching coronavirus in the future—and therefore 
also·
 ► Lower risk of passing it on to others.
Those who test ‘positive’ would get an immunity passport.
They could return to work early.
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region based on prior results showing these are predic-
tors of risk beliefs.
Binary logistic regressions were run (as above) for 
the secondary outcomes: intention to wash hands less, 
intention to avoid physical contact less and intention to 
undergo the test. Unadjusted and adjusted ORs (AOR) 
and 95% CIs are reported. Logistic regression was run 
to assess the extent to which intentions to engage in less 
frequent hand washing or social distancing measures is 
predicted by perceiving the test result to mean no risk of 
being infected in the future by coronavirus.
As only a very small proportion of participants gave 
a ‘zero’ response on the sliding scale of future risk, we 
used a linear regression model to examine this outcome, 
rather than a binary (zero vs other) logistic regression as 
prespecified in the analysis plan.
Procedure
Data were collected using an online survey platform, 
Predictiv. On entry to the study, participants were informed 
that they were to be asked some questions about corona-
virus and that it would take about 5 min to complete. Partic-
ipants were then shown one of six brief descriptions of an 
antibody test for coronavirus (see online supplementary 
material S1 for full text for each of the six descriptions). 
They were then asked five questions, assessing the primary 
and secondary outcomes. Participants’ demographic char-
acteristics were accessed from the survey platform.
RESULTS
Sample characteristics
The sample comprised 606 women and 598 men with 
a median age of 36 years. Around a quarter had some 
Table 2 Primary and secondary outcomes by experimental group (n=1204)
Immunity Antibody
All Passport Certificate Test Passport Certificate Test
(n=1204) (n=187) (n=235) (n=179) (n=219) (n=209) (n=175)
Perceived meaning of result for future risk, n (%)
  No risk 174 (14.5) 26 (13.9) 50 (21.3) 39 (21.8) 24 (11.0) 19 (9.1) 16 (9.1)
  Lower risk (in line 
with description)
697 (57.9) 106 (56.7) 127 (54.0) 92 (51.4) 126 (57.5) 134 (64.1) 112 (64.0)
  Average risk 248 (20.6) 40 (21.4) 42 (17.9) 36 (20.1) 54 (24.7) 41 (19.6) 35 (20.0)
  Higher risk 85 (7.1) 15 (8.0) 16 (6.8) 12 (6.7) 15 (6.8) 15 (7.2) 12 (6.9)
Perceived absolute 
risk (0–100) (mean 
(SD))
37.7 (25.2) 40.4 (26.5) 37.0 (25.4) 34.2 (27.1) 39.5 (23.6) 36.9 (25.2) 37.9 (23.1)
Perceived residual risk, n (%)
  1%–100% 1144 (95.0) 179 (95.7) 219 (93.2) 161 (89.9) 214 (97.7) 200 (95.7) 171 (97.7)
  0% 60 (5.0) 8 (4.3) 16 (6.8) 18 (10.1) 5 (2.3) 9 (4.3) 4 (2.3)
Intention to wash hands, n (%)
  Much less than 
now
13 (1.1) 3 (1.6) 7 (3.0) 0 (0.0) 0 (0.0) 2 (1.0) 1 (0.6)
  Less than now 46 (3.8) 6 (3.2) 11 (4.7) 7 (3.9) 8 (3.7) 10 (4.8) 4 (2.3)
  Same as now 800 (66.4) 121 (64.7) 159 (67.7) 127 (70.9) 138 (63.0) 143 (68.4) 112 (64.0)
  More than now 161 (13.4) 23 (12.3) 26 (11.1) 18 (10.1) 34 (15.5) 29 (13.9) 31 (17.7)
  Much more than 
now
184 (15.3) 34 (18.2) 32 (13.6) 27 (15.1) 39 (17.8) 25 (12.0) 27 (15.4)
Intention to avoid physical contact, n (%)
  Much less than 
now
36 (3.0) 2 (1.1) 9 (3.8) 10 (5.6) 4 (1.8) 6 (2.9) 5 (2.9)
  Less than now 201 (16.7) 35 (18.7) 48 (20.4) 29 (16.2) 32 (14.6) 33 (15.8) 24 (13.7)
  Same as now 642 (53.3) 96 (51.3) 116 (49.4) 96 (53.6) 116 (53.0) 126 (60.3) 92 (52.6)
  More than now 178 (14.8) 28 (15.0) 34 (14.5) 21 (11.7) 44 (20.1) 27 (12.9) 24 (13.7)
  Much more than 
now
147 (12.2) 26 (13.9) 28 (11.9) 23 (12.8) 23 (10.5) 17 (8.1) 30 (17.1)
Would you have the test if offered? n (%)
  No, definitely not 38 (3.2) 5 (2.7) 14 (6.0) 5 (2.8) 5 (2.3) 4 (1.9) 5 (2.9)
  No, probably not 140 (11.6) 24 (12.8) 28 (11.9) 23 (12.8) 23 (10.5) 20 (9.6) 22 (12.6)
  Yes, probably 351 (29.2) 54 (28.9) 67 (28.5) 53 (29.6) 62 (28.3) 58 (27.8) 57 (32.6)
  Yes, definitely 675 (56.1) 104 (55.6) 126 (53.6) 98 (54.7) 129 (58.9) 127 (60.8) 91 (52.0)
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graduate- level education (24.2%) and there was good 
representation of all UK regions (see table 1). Distribu-
tion of sample characteristics by exposure group is shown 
in table 1.
Descriptive statistics
Primary outcome
Responses to the five outcome questions for the whole 
sample and by experimental group are shown in table 2. 
Overall, 14.5% of respondents (95% CI 12.5% to 16.6%) 
interpreted the test result as meaning they had no risk 
of future infection. Over half (57.9% (95% CI 55.0% to 
60.1%)) interpreted the test result as meaning that their 
future risk of coronavirus was ‘lower’, in line with the 
description they had been given.
Secondary outcomes
Perceived level of future risk (on a scale of 0%–100%) 
showed a complex, trimodal distribution. The median 
was 35% with an IQR from 18% to 51%. Only 5% of 
respondents put their risk at 0%. Overall, 63% put their 
risk below 50%. Ten per cent put their risk at 50%, which 
was the modal response. Twenty- four per cent put their 
risk at greater than 50%, but below 100%. Three per cent 
of respondents put their risk at 100%: that is, they said 
they were certain to contract the virus. There was a lack of 
consistency between responses to the categorical and the 
continuous measures of risk. Median responses on the 
sliding scale were 12.5%, 28.0%, 50.0% and 65.0% in the 
‘no risk’, ‘lower risk’, ‘average risk’ and ‘higher risk’ cate-
gories, respectively, with responses ranging from 0 to 100 
for all four of these groups. Although this suggests that a 
proportion of people were responding very differently to 
the two questions (eg, ‘no risk’ on the first outcome and 
100% risk on the sliding scale), the increasing median 
responses with increasing risk category provide some 
reassurance that most people’s responses were broadly 
consistent across the two measures.
On the behavioural outcomes, 4.9% (95% CI 3.8% to 
6.3%) said they would wash their hands less frequently 
than now if they received a positive result while 19.7% 
(95% CI 17.5% to 22.1%) said they would be less inclined 
to avoid physical contact with others outside the home. 
Intentions to have the test if offered were high, with 
56.1% (95% CI 53.2% to 58.9%) saying they would defi-
nitely, and 29.2% (95% CI 26.6% to 31.8%) saying they 
would probably have the test if offered today.
Between-group differences in the primary outcome
When test type (Immunity vs Antibody), result type 
(Certificate vs Passport vs Test) and an interaction term 
were entered into a logistic regression model predicting 
the belief that the test result meant ‘no risk’ of future 
infection (see table 3), there was a significant effect of test 
type, which persisted when we adjusted for demographic 
factors (age (including a quadratic term), gender, educa-
tion level and UK region; AOR: 2.91 (95% CI 1.52 to 
5.55)). Those in the ‘Immunity’ group were more likely 
to believe the result meant ‘no risk’ than those in the 
Antibody group (19.1% (95% CI 16.1% to 22.5%) vs 9.8% 
(95% CI 7.5% to 12.4%)) (figure 1). There was no signif-
icant effect of result type and no significant interaction.
Between-group differences in secondary outcomes
We analysed the continuous measures of future perceived 
risk of infection using a linear model (analysis of variance) 
with two levels for test type, three levels for result type and 
an interaction term. Overall, there was no significant effect: 
Table 3 Logistic regression analysis examining impact of test type and result type on perception that the test result means 
‘no risk’
Proportion answering ‘no risk’ 
in each subgroup
% (95% CI) (n=1204)
Result means ‘no risk’ of future infection
OR (95% CI)
Mutually adjusted (n=1204)
Adjusted for demographics* 
(n=1179)
Test type
  Antibody (n=603) 9.8 (7.5 to 12.4) Ref Ref
  Immunity (n=601) 19.1 (16.1 to 22.5) 2.77 (1.48 to 5.17) 2.91 (1.52 to 5.55)
Result type
  Test (n=354) 15.5 (11.9 to 19.7) Ref Ref
  Certificate (n=444) 15.5 (12.3 to 19.3) 0.99 (0.50 to 2.00) 0.96 (0.47 to 1.99)
  Passport (n=406) 12.3 (9.3 to 15.9) 1.22 (0.63 to 2.38) 1.24 (0.62 to 2.48)
Test by result interaction
  Certificate by 
immunity result
0.98 (0.42 to 2.27) 1.00 (0.42 to 2.40)
  Passport by immunity 
result
0.47 (0.20 to 1.12) 0.46 (0.19 to 1.12)
Bold indicates statistical significance (p<.05)
*Fully adjusted model includes age (with quadratic term), gender, education level and region (coded as per table 1).
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F5,1198=1.46, p=0.20, adjusted R
2<1%. We repeated the anal-
ysis adjusting for demographic factors as covariates. Overall, 
there was a significant effect: F13,1165=1.88, p=0.03, adjusted 
R2=1%. This was because of a significant effect of age: as age 
increased, perceived risk decreased. There remained no 
significant effect of the experimental variables.
Logistic regression analyses examining the impact of test 
type, result type and their interaction on intentions to wash 
hands and avoid physical contact less frequently and on will-
ingness to have the test are shown in online supplementary 
tables 1 and 2. Neither test type, result type nor their inter-
action was significantly associated with these behavioural 
outcomes.
Association between test result meaning ‘no risk’ and 
behavioural intentions
Logistic regression analyses were used to examine belief 
that the result meant ‘no risk’ as a predictor of intention 
to wash hands and avoid physical contact less frequently, 
given a positive test result (see figure 2 and online 
Figure 1 Proportion believing an antibody- positive test result means ‘no risk’ of future infection. Error bars show 95% CIs.
Figure 2 Perceived meaning of an antibody- positive test result for future risk and intentions to reduce frequency of hand 
washing. Error bars show 95% CIs.
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supplementary table 3). In analyses adjusting for demo-
graphic factors, those who believed there was no residual 
risk were at increased odds of intending to wash their 
hands less (AOR: 2.32 (95% CI 1.25 to 4.28)). The asso-
ciation with intentions to avoid physical contact was not 
significant (AOR: 1.37 (95% CI 0.93 to 2.03)).
DISCUSSION
Using the term Immunity—as opposed to Antibody—
to describe antibody tests for SARS- CoV-2 doubled the 
proportion who erroneously perceived they would have 
no risk of becoming infected with the virus in the future if 
they were given an antibody- positive test result, from 9.8% 
for Antibody to 19.1% for Immunity (AOR: 2.91 (95% 
CI 1.52 to 5.55)). Using the terms Passport, Certificate 
or Test to describe the results had no significant effect 
on risk perception (AOR: 0.96 (95% CI 0.47 to 1.99) for 
Certificate and 1.24 (95% CI 0.62 to 2.48) for Passport, 
compared with Test). The terms used to describe the test 
and results had no significant direct impact on intentions 
to engage in the protective behaviours of hand washing or 
physical distancing. However, across conditions, a greater 
proportion of those perceiving the result to mean no risk 
intended to wash their hands less often (10.3% (95% CI 
6.3% to 15.9%)) compared with 4.0% who understood 
there was a residual risk (4.3% (95% CI 2.8% to 5.3%)).
There was no significant association with intended 
frequency of avoiding physical contact with others outside 
of the home. Interest in undergoing the test was high—
with 85.2% saying they would probably or definitely have 
it if offered—and was unaffected by the terms used to 
describe the tests.
This study was designed to test two hypotheses, providing 
strong support for the first, that describing a test indi-
cating the presence of antibodies using the term Immu-
nity (vs Antibody) increases the likelihood that those with 
this test result erroneously perceive they have no risk of 
becoming infected in the future with coronavirus. This 
likely reflects a certainty about risk of future infection 
implicit in lay understandings of the term immunity that 
is not implied by the term antibody.17 Qualitative studies 
could explore this and other potential mechanisms for 
the effect observed.
The results of this study did not support the second 
hypothesis that describing test results as Passports or 
Certificates increases the likelihood that those with 
this test result erroneously perceive they have no risk 
of becoming infected in the future with coronavirus. 
This does not mean that these terms are unproblematic 
however, only that they did not influence the specific 
perceptions that we explored. Qualitative studies are 
warranted to understand the broader meanings these 
terms have in the context of testing for antibodies for 
SARS- CoV-2 and other contexts.
Responses on the sliding scale of future risk showed 
a high variability and were largely unexplained by the 
experimental intervention or other variables measured. 
They also showed only broad consistency with responses 
to the main outcome measure; some participants who 
believed the result meant ‘no risk’ then rated their future 
risk as 100%, and vice versa. This may point to consider-
able uncertainty in the public as to how to interpret test 
results and is consistent with the literature on risk commu-
nication and perception.18 19 Some participants may have 
been responding solely on the information provided; 
others may have been using other information about coro-
navirus and immunity to make judgements about their 
own risk. It also likely reflects the well- described tendency 
of people to use a 50% response to indicate uncertainty 
rather than a true judgement of probability.20 We also saw 
that about a quarter of respondents on the first question 
stated their risk was ‘average’ or ‘higher’. Use of the top 
end of the scale is hard to interpret but may either reflect 
participants’ not reading the information carefully and 
therefore misunderstanding the meaning of the result 
being communicated in the information, or their using 
information beyond the experiment to assess their risk. 
Participants likely considered many factors in making 
sense of the hypothetical result, such as their actual risk of 
contracting the virus based on their behaviour and likely 
exposure. Only 7% of the sample responded that their 
risk would be higher on the primary outcome measure. 
Reasons for this are unclear.
While we found no evidence for a direct effect on 
protective behaviours of the terms used to describe 
antibody test results, there was indirect evidence that 
perceiving no risk of future infection might reduce 
frequency of hand washing. This finding is tentative, 
given it is based on behavioural intentions in response to 
a hypothetical antibody- positive result. Nonetheless, the 
potential for antibody testing to increase viral transmis-
sion must be considered alongside the potential benefits 
the tests might have in allowing the easing of lockdown 
restrictions. Clear communication about the ongoing 
need for hand washing, in particular, will be essential 
and raising public awareness of the main mechanisms 
through which SARS- CoV-2 is transmitted—through air 
and surfaces—might help improve adherence. This, in 
addition to acknowledgement of the imperfect nature 
of the tests, will give the public a more accurate repre-
sentation of the meaning and implications of an anti-
body test result and a better understanding of how to 
reduce the risk of transmission. Such communications 
need to emphasise that transmission can occur through 
contact regardless of antibody status. Such communi-
cations also need to be rigorously evaluated to ensure 
their effectiveness at communicating these points both 
to those undergoing antibody tests as well as to general 
populations that are now having to learn to live with 
SARS- CoV-2.
It was notable that 85% of respondents said that they 
would probably or definitely have an antibody test if they 
were offered it. This suggests high interest but should 
be treated with caution not least because fewer undergo 
than express interest in undergoing tests.21
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Strengths and limitations
This study provides the first experimental evidence for the 
potentially adverse impact on risk perceptions and protective 
behaviours of commonly used terms to describe SARS- CoV-2 
antibody tests and their results. As such, it provides timely 
evidence to inform policy and research to mitigate these 
effects to realise the potential benefits of such tests.
The study has several limitations. First, participants were 
responding to a hypothetical test and asked to imagine 
that they had received a test result that had detected anti-
bodies. The extent to which people responded using the 
information provided in the study is unknown. Some will 
likely have used other information about SARS- CoV-2 
and their own experiences to answer the questions about 
risk. This is a limitation of all hypothetical scenario- based 
studies of this type but findings from such studies can 
generalise to clinical settings22 23 although some caution 
is warranted. As antibody testing is not yet routinely being 
carried out in the UK, the impact of the wording used in 
the current study among those undergoing testing cannot 
be assessed. All scenarios used the term ‘positive’ so we 
were unable to examine any possible impact of the use 
of this term. In addition, due to the rapidity with which 
the current study was conducted, piloting of the materials 
in general population samples was not carried out. It is 
therefore possible that some of the information provided 
may have been misinterpreted.
Second, the protective behaviours of hand washing 
and physical distancing were measured using single items 
assessing behavioural intentions following a hypothetical 
test result.
Third, the sample size was insufficient to detect effect 
sizes that could be important at a population level. It is 
possible, for example, that the use of the terms Certifi-
cate or Passport might impact on risk perception, but the 
current study lacked the power to detect this.
Fourth, while quotas were used to achieve a sample 
broadly representative of the UK population, research 
panels are not representative of the general popula-
tion.24 25 We found no evidence that the impact of the 
interventions in this study was modified by demographic 
characteristics of the participants, providing some reas-
surance about the generalisability of results across age 
groups, gender, educational level and geographical 
region of the UK.
Implications for research and policy
The results of this study have several implications for 
research and policy. Our finding that 85% of people were 
positively inclined towards having a test is encouraging 
for any future antibody testing programme. The effec-
tiveness of antibody tests for SARS- CoV-2 will depend on 
high uptake, the extent and duration of any immunity 
conferred and the performance of a test, as well as on a 
good understanding of the meaning of test results among 
those who participate. First, the use of the term Immunity 
should be avoided in phrases to describe antibody tests, 
whether described as Passports, Certificates or Tests. This 
has implications for the presentation of antibody testing 
by policymakers and the media, as well as those consid-
ering the wording of test result letters sent to tested indi-
viduals. Second, research is needed to evaluate different 
ways of informing those offered tests and receiving 
test results to minimise the proportion erroneously 
perceiving an antibody- positive test result to mean no risk 
of becoming infected with the virus. It should also focus 
on maximising understanding that—regardless of anti-
body status—anyone can indirectly transmit the virus by 
touching a contaminated surface and infecting the next 
surface they touch. Hand washing or sanitising therefore 
needs to remain frequent. Research is also needed with 
those undergoing actual tests, powered to detect effects 
judged meaningful in the context of a population- based 
testing programme and involving measures of actual 
behaviour.
CONCLUSION
Interest in SARS- CoV-2 antibody testing is high—across 
many countries, employers and populations. While such 
testing could contribute to wider strategies to ease lock-
down restrictions, their use may have an adverse impact 
on transmission- related behaviour. This appears to vary 
with the way the tests are described. Using the term Immu-
nity (vs Antibody) to describe antibody tests increases the 
proportion of people believing that an antibody- positive 
result means they have no future risk of coronavirus, a 
perception that may be associated with less frequent hand 
washing and hence increased risk of transmission.
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